Subjects at risk of discontinuation of lipid-lowering agents: A 6-month cohort study among 12,875 patients in a Chinese population

Clinical Therapeutics

Volumn 33, Issue 5, 2011, Pages 617-628

  Wong, Martin C S ^a   Jiang, Johnny Y ^b   Yan, Bryan P ^a   Griffiths, Sian M ^a  

^a Prince of Wales Hospital   (Hong Kong)

^b PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Associated factors; Drug discontinuation; Ethnic Chinese; Lipid lowering agents; Pharmacovigilance

Indexed keywords

ANTILIPEMIC AGENT; BILE ACID SEQUESTRANT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID DERIVATIVE; SELECTIVE CHOLESTEROL ABSORPTION INHIBITOR; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; AGED; ANGINA PECTORIS; ARTICLE; CEREBROVASCULAR ACCIDENT; CHINESE; COHORT ANALYSIS; COMORBIDITY; DIABETES MELLITUS; DRUG COMBINATION; FEMALE; FOLLOW UP; GLOMERULONEPHRITIS; HEART DISEASE; HEART FAILURE; HONG KONG; HUMAN; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NEPHROSIS; PATIENT COMPLIANCE; PRESCRIPTION; PRIMARY MEDICAL CARE; RURAL AREA;

EID: 79958758238     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.04.019     Document Type: Article

References (43)

1. Anderson K.M., Castelli W.P., Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA 1987, 257:2176-2180.
2. Nickening G. Central role of the AT(1)-receptor in atherosclerosis. J Hum Hypertens 2002, 16(Suppl 3):S26-S33.
3. Nickening G., Harrison D.G. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: Part II: AT(1) receptor regulation. Circulation 2002, 105:530-536.
4. Nickening G., Harrison D.G. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: Part I: oxidative stress and atherogenesis. Circulation 2002, 105:393-396.
5. Goldberg R.J., Burchfiel C.M., Benfante R., et al. Lifestyle and biologic factors associated with atherosclerotic disease in middle-aged men: 20-year findings from the Honolulu Heart Program. Arch Intern Med 1995, 155:686-694.
6. Reaven G.M., Lithell H., Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistance and sympathoadrenal system. N Engl J Med 1996, 334:374-381.
7. Oparil S., Zaman M.A., Calhoun D.A. Pathogenesis of hypertension. Ann Intern Med 2003, 139:761-776.
8. Haffner S.M., Miettinen H., Gaskill S.P., Stern M.P. Metabolic precursors of hypertension: the San Antonio Heart Study. Arch Intern Med 1996, 156:1994-2000.
9. Hunt S.C., Stephenson S.H., Hopkins P.N., Williams R.R. Predictors of an increased risk of future hypertension in Utah. A screening analysis. Hypertension 1991, 17:969-976.
10. Ferrier K.E., Muhlmann M.H., Baguet J.P., et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002, 39:1020-1025.
11. Borghi C., Dormi A., Veronesi M., et al. Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am Heart J 2004, 148:285-292.
12. Halperin R.O., Sesso H.D., Ma J., et al. Dyslipidemia and the risk of incident hypertension in men. Hypertension 2006, 47:45-50.
13. Lip G.Y.H., Hall J.E. Comprehensive Hypertension 2007, Mosby, Philadelphia, Pa.
14. Borghi C. Interactions between hypercholesterolemia and hypertension: implications for therapy. Curr Opin Nephrol Hypertens 2002, 11:489-496.
15. Neaton J.D., Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316,009 white men. Arch Intern Med 1992, 152:56-64.
16. Borghi C., Veronisi M., Bacchelli S., et al. Serum cholesterol levels, blood pressure response to stress and incidence of stable hypertension in young subjects with high normal blood pressure. J Hypertens 2004, 22:265-272.
17. Felmeden D.C., Spencer C.G.C., Blann A.D., et al. Low-density lipoprotein subfractions and cardiovascular risk in hypertension: relationship to endothelial dysfunction and effects of treatment. Hypertension 2003, 41:528-533.
18. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2005, 48:2482-2485.
19. Sever P.S., Poulter N.R., Dahlof B., et al. The Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm: extended observation 2 years after trial closure. Eur Heart J 2008, 29:499-508.
20. Ellis J.J., Erickson S.R., Stevenson J.G., et al. Suboptimal statin adherence and discontinuation in primary and secondary prevention population. J Gen Intern Med 2004, 19:638-645.
21. Benner J.S., Glynn R.J., Mogun H., et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002, 288:455-461.
22. Bi Y., Gao R., Patel A., et al. Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study. Am Heart J 2009, 157:509-516.e1.
23. Cheng C.W., Woo K.S., Chan J.C., et al. Association between adherence to statin therapy and lipid control in Hong Kong Chinese patients at high risk of coronary heart disease. Br J Clin Pharmacol 2004, 58:528-535.
24. Wong M.C.S., Jiang J.Y., Gibbs T., Griffiths S. Factors associated with antihypertensive drug discontinuation among Chinese patients: a cohort study. Am J Hypertens 2009, 22:802-810.
25. HA and Clinical Research-Support, Output and Direction Accessed December 4, 2009. http://www.ha.org.hk/ho/research_ethics/msdc_p181.pdf.
26. Wong M.C., Jiang J.Y., Tang J.L., et al. Health services research in the public healthcare system in Hong Kong: an analysis of over 1 million antihypertensive prescriptions between 2004-2007 as an example of the potential and pitfalls of using routinely collected electronic patient data. BMC Health Serv Res 2008, 8:138.
27. Statistical tables of the 2006 population by-census. Hong Kong Special Administrative Region, China Accessed December 27, 2009. http://www.bycensus2006.gov.hk/en/data/data3/index.htm.
28. MacDonald T.M., Morant S.V., Mozaffari E. Drug treatment discontinuation and achievement of target blood pressure and cholesterol in United Kingdom primary care. Curr Med Res Opin 2007, 23:2765-2774.
29. Avorn J., Monette J., Lacour A., et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998, 279:1458-1462.
30. Melloni C., Alexander K.P., Ou F.S., et al. Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome. Am J Cardiol 2009, 104:175-181.
31. Wong M.C., Jiang J.Y., Lam A.T., et al. Patterns of antihypertensive prescribing, discontinuation and switching among a Hong Kong Chinese population from over one million prescriptions. J Hum Hypertens 2008, 22:714-716.
32. Wong M.C., Jiang J.Y., Griffiths S.M. Switching of antihypertensive drugs among 93,286 Chinese patients: a cohort study. J Hum Hypertens 2010, 24:669-677.
33. Wong M.C., Jiang J.Y., Griffiths S.M. Adherence to combination therapy among ethnic Chinese patients: a cohort study. Hypertens Res 2010, 33:416-421.
34. Wong M.C., Jiang J.Y., Griffiths S.M. Factors associated with compliance, discontinuation and switching of calcium channel blockers in 20,156 Chinese patients. Am J Hypertens 2009, 22:904-910.
35. Wong M.C., Jiang J.Y., Griffiths S.M. Short-term adherence to beta-blocker therapy among ethnic Chinese patients with hypertension: a cohort study. Clin Ther 2009, 31:2170-2177.
36. Wong M.C., Jiang J.Y., Griffiths S.M. Antihypertensive drug adherence among 6408 Chinese patients on angiotensin-converting enzyme inhibitors: a cohort study. J Clin Pharmacol 2010, 50:598-605.
37. Wong M.C., Jiang J.Y., Griffiths S.M. Factors associated with antihypertensive drug compliance in 83,884 Chinese patients: a cohort study. J Epidemiol Community Health 2010, 64:895-901.
38. Monane M., Matthias D.M., Nagle B.A., Kelly M.A. Improving prescribing patterns for the elderly through an online drug utilization review intervention: a system linking physician, pharmacist, and computer. JAMA 1998, 280:1249-1252.
39. Cramer J.A. Enhancing patient compliance in the elderly. Role of packaging aids and monitoring. Drugs Aging 1998, 12:7-15.
40. Young I.S., Loughrey B.V. Lipid-lowering therapy. Comprehensive Hypertension 2007, Mosby, Philadelphia, Pa. G.Y. Lip, J.E. Hall (Eds.).
41. Carter B.L. Adherence, quality of life, cost effectivness, and the role of the pharmacist. Comprehensive Hypertension 2007, Mosby, Philadelphia, Pa. G.Y.H. Lip, J.E. Hall (Eds.).
42. Halpern M.T., Khan Z.M., Schmier J.K., et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension 2006, 47:1039-1048.
43. Donovan J.L. Patient decision making: the missing ingredient in compliance research. Int J Technol Assess Health Care 1995, 11:443-455.